Experimental Medicine Approaches in Early-Phase CNS Drug Development

Area of Science:

• Clinical Pharmacology
• Neuroscience Drug Development
• Biomarker Research

Background:

• Phase 1 trials traditionally focused on safety and pharmacokinetics in healthy volunteers.
• Central nervous system (CNS) drug development faces high failure rates in later phases.
• This necessitates an evolution in early-phase trial design.

Purpose of the Study:

• To discuss the evolving landscape of Phase 1 clinical trials in the CNS therapeutic area.
• To highlight novel methodologies and approaches being incorporated.
• To improve early pharmacologic understanding of CNS-active compounds.

Main Methods:

• Incorporation of novel study designs.
• Inclusion of pharmacodynamic biomarkers.
• Early inclusion of patients in Phase 1 trials.
• Application of experimental medicine approaches.

Main Results:

• The abstract does not contain results, it is a chapter discussing changes in trial design.

Conclusions:

• Phase 1 CNS trials are shifting towards earlier patient involvement and biomarker integration.
• These changes aim to enhance early decision-making and improve the success rate of CNS drug development.
• Novel trial designs and experimental medicine approaches are key to this evolution.